Improvement in progressive multifocal leukoencephalopathy after pembrolizumab‐induced immune reconstruction inflammatory syndrome in a patient with follicular lymphoma

Progressive multifocal leukoencephalopathy (PML) may develop in follicular lymphoma patients treated with bendamustine‐rituximab. In this report, treatment with pembrolizumab successfully inhibited the clinical progression of PML by promoting radiologically demonstrated immune restoration inflammato...

Descripción completa

Detalles Bibliográficos
Autores principales: Dufour, Inès, Duprez, Thierry, Wertz, Marie, Saussoy, Pascale, Ackermans, Nathalie, El Sankari, Souraya, van Pesch, Vincent, Van Den Neste, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175693/
https://www.ncbi.nlm.nih.gov/pubmed/35845001
http://dx.doi.org/10.1002/jha2.56
Descripción
Sumario:Progressive multifocal leukoencephalopathy (PML) may develop in follicular lymphoma patients treated with bendamustine‐rituximab. In this report, treatment with pembrolizumab successfully inhibited the clinical progression of PML by promoting radiologically demonstrated immune restoration inflammatory syndrome (IRIS), allowing complete clearance of the virus. These findings may further support the use of pembrolizumab in PML with special consideration for the potential occurrence of IRIS.

Ejemplares similares